|
市場調査レポート
商品コード
1172706
腱炎治療の世界市場の規模、シェア、産業動向分析レポート:タイプ別(治療法、手術)、治療法タイプ別(物理療法、温冷療法、衝撃波療法)、症状別、地域別展望・予測、2022年~2028年Global Tendonitis Treatment Market Size, Share & Industry Trends Analysis Report By Type (Therapy and Surgery), By Therapy Type (Physical Therapy, Hot & Cold Therapy and Shockwave Therapy), By Condition, By Regional Outlook and Forecast, 2022 - 2028 |
||||||
腱炎治療の世界市場の規模、シェア、産業動向分析レポート:タイプ別(治療法、手術)、治療法タイプ別(物理療法、温冷療法、衝撃波療法)、症状別、地域別展望・予測、2022年~2028年 |
出版日: 2022年11月30日
発行: KBV Research
ページ情報: 英文 221 Pages
納期: 即納可能
|
腱炎治療の世界市場規模は、予測期間中にCAGR3.7%で成長し、2028年には2523億米ドルに達すると予測されます。
痛みの緩和と炎症の軽減が腱炎治療の目標です。一般的な家庭での治療法としては、安静、温熱・氷嚢、市販の鎮痛剤などがあります。それでも症状が改善されない場合は、医師からさらなる処置が提案されることもあります。
使いすぎの結果、腱炎になることがあります。腱を休ませることで、炎症を抑えることができます。腱炎の引き金となったスポーツや繰り返しの動作を控える必要があります。包帯、スプリント、装具の助けを借りて、動きを制限することができます。
COVID-19影響分析
パンデミックは、主要プレイヤーのサプライチェーン、オペレーション、製品流通、生産、およびその他の商業ベンチャーに影響を与えました。業界の多くの事業者が、腱炎治療グッズの売り上げ減少を報告しました。ヘルスケア施設では、個人用保護具(PPE)の不足、熟練労働者の不足、制限、施錠などの要因により、治療のスケジュール変更、重要性の有無の優先順位付けを余儀なくされました。パンデミック期間中の市場成長の低下は、腱炎治療のためのさまざまな理学療法や外科的技術がパンデミック期間中に必要ないと判断されたことと関連する可能性があります。このことは、今後数年間、ポジティブな成長見通しをもたらすでしょう。
市場成長要因
スポーツ傷害の発生率の上昇
アマチュアスポーツや活動レベルの上昇、世界の主要市場における人口の高齢化はすべて、腱炎のハイエンド治療に対する需要を高めると予測されます。腱炎は通常、膝、手首、足首の腱の使い過ぎや反復的なストレスによって引き起こされます。このため、腱炎は、バスケットボール、サッカー、ダウンヒルスキー、体操、サッカーなど、需要の高いスポーツの参加者を苦しめる最も一般的なケガです。
増加する整形外科疾患の症例
整形外科的損傷は、深刻な整形外科的疾患の有病率が世界的に増加していることから、公衆衛生の観点から懸念される重要な理由となっています。テニス肘、投手肘、水泳肩、アキレス腱炎などの有病率が上昇していることが、この懸念の要因となっています。また、世界的に肥満の人が増えていることも大きな特徴です。肥満の人は、糖尿病や整形外科的疾患、筋骨格系疾患を発症しやすいと言われています。
市場抑制要因
パンデミック期の深刻な影響
腱炎治療市場は、傷害の再発、治療の遅れ、治療の効果の低さ、それに伴う副作用によって阻害されています。COVID-19の流行は、腱炎の管理方法に大きな影響を及ぼしています。一時的な閉鎖、渡航制限、ヘルスケア施設での感染者数の増加などは、すべて業界に悪影響を及ぼしました。腱炎を治療できる熟練したヘルスケア専門家が不足しているため、流行が遅れているのです。
タイプ別展望
腱炎治療市場は、タイプ別に治療法(温熱・冷却療法、理学療法、衝撃波療法)と手術に分類されます。手術分野は、2021年の腱炎治療市場で大きな収益シェアを獲得しました。薬物療法に反応しない重傷の腱に対して、外科手術は治療戦略の最後の手段です。
病態の展望
コンディション別に見ると、腱炎治療市場は、テニス肘、ゴルファー肘、投手肘、ジャンパー膝、水泳肩、アキレス腱炎に細分化されます。2021年の腱炎治療市場では、アキレス腱炎分野が最も高い収益シェアを示しています。人体で最も大きな腱はアキレス腱です。ランニングやジャンプによってアキレス腱が伸びたり切れたりすることで、腱炎になることがあります。アキレス腱炎にかかる人は非常に多く、そのほとんどはレクリエーションスポーツに従事したときに破裂します。
地域別の展望
地域別に見ると、腱炎治療市場は北米、欧州、アジア太平洋、LAMEAで分析されています。2021年には、北米地域が最大の収益シェアを獲得し、腱炎治療市場をリードしました。同地域の成長に寄与するいくつかの要素には、そこで行われる腱炎処置の数の増加や、消費者の可処分所得水準の上昇などがあります。この地域の産業は、地元の医療機器メーカーのイントロダクションや、定評ある有名企業との提携によって、大きな成長の可能性が生み出されています。
The Global Tendonitis Treatment Market size is expected to reach $252.3 billion by 2028, rising at a market growth of 3.7% CAGR during the forecast period.
When the tendons-a flexible but inelastic cord of tissue linking the bone to the muscle become inflamed or irritated, the disease is referred to as tendonitis. Pain, loss of movement, and inflammation from tendonitis are just a few of the issues that can result from this disease. Mild swelling, frozen shoulder, and discomfort are a few of the signs of tendonitis.
Although a sudden injury might result in tendinitis, the condition is far more likely to develop by repeatedly performing a certain movement over time. Most tendinitis cases are brought on by repetitive motions from work or hobbies that strain the tendons. It's crucial to use good technique when engaging in repetitive work- or sports-related activities. Tennis elbow is one example of how improper technique can overload the tendon and cause tendonitis.
Pain relief and inflammation reduction are the goals of tendinitis treatment. Common home remedies include rest, heat and ice packs, and over-the-counter painkillers. Further measures may be suggested by a doctor if they do not help a person's symptoms.
A result of overuse is tendinitis. The inflammation can be reduced by giving the injured tendon some rest. The person should refrain from the sport or repetitive motion that triggered the tendonitis. Movement can be limited with the aid of a bandage, splint, or brace.
The pandemic had an impact on the major players' supply chains, operations, product distribution, production, and other commercial ventures. Many businesses in the industry have reported a reduction in sales of their tendonitis treatment goods. The healthcare facilities were compelled to reschedule and prioritize treatments as important or not due to factors such as a lack of Personal Protective Equipment (PPE), a skilled workforce, restrictions, and lockdowns. A reduction in market growth during the pandemic can be linked to the fact that various physical therapy and surgical techniques for tendonitis treatment were not deemed necessary during the pandemic period. This will provide positive growth prospects in the upcoming years.
The rise in amateur sports and activity levels, and the ageing of the population in key markets around the world, are all predicted to increase demand for high-end treatment of tendonitis. Tendonitis is typically brought on by the overuse or repetitive stress of tendons in the knee, wrist, or ankle. Due to this, tendonitis is the most common injury afflicting participants in high-demand sports including basketball, football, downhill skiing, gymnastics, and soccer.
Orthopedic injuries are a key reason for concern in terms of public health as the prevalence of serious orthopedic diseases is increasing globally. Some of the factors contributing to this cause of concern are the rising prevalence of tennis elbow, pitcher's elbow, swimmer's shoulder, and Achilles tendonitis. Another crucial sign is the rise in the number of obese persons in the world. Obese people are much more likely to acquire diabetes, as well as orthopedic and musculoskeletal conditions.
The tendonitis treatment market is being hampered by recurring injuries, delay, and the ineffectiveness of treatments, along with the associated side effects. The Covid-19 outbreak has had a profound impact on how tendinitis is managed. Temporary lockdowns, travel restrictions, and an increase in the number of infections in healthcare facilities have all had a negative influence on the industry. Due to a shortage of skilled healthcare professionals who can treat tendinitis, the epidemic has been delayed.
Based on type, the tendonitis treatment market is segmented into therapy (hot & cold therapy, physical therapy, shockwave therapy) and surgery. The surgery segment acquired a significant revenue share in the tendonitis treatment market in 2021. For severely injured tendons that are unresponsive to pharmacological therapy, surgical operations are the last resort in the treatment strategy.
On the basis of condition, the tendonitis treatment market is fragmented into tennis elbow, golfer's elbow, pitcher's elbow, jumper's knee, swimmer's shoulder and achilles tendonitis. In 2021, the Achilles tendonitis segment witnessed the highest revenue share in the tendonitis treatment market. The largest tendon in the human body is the Achilles tendon. Running and jumping can stretch and rupture the Achilles tendon, which results in tendinitis. A large number of people are affected by Achilles tendinitis, and most of the ruptures happen when engaging in recreational sports.
Region wise, the tendonitis treatment market is analyzed across the North America, Europe, Asia Pacific and LAMEA. In 2021, the North America region led the tendonitis treatment market by generating the largest revenue share. The few elements that contribute to the region's growth include an increase in the number of tendonitis procedures performed there and rising consumer disposable income levels. Significant growth potential for the industry in the region is being created by the introduction of local medical device manufacturers and partnerships with established & famous firms.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck & Co., Inc., Bayer AG, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Abbott Laboratories, Pfizer, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., and Almatica Pharma, Inc.
Aug-2020: Teva came into a partnership with Alvotech, a global biopharmaceutical company focused on the development & manufacturing of high-quality biosimilars for worldwide markets. This partnership would enable Teva to lend its technical expertise in working with the FDA to bring products to the U.S. market along with broadening its growing biosimilar portfolio as well as continuing to leverage its exceptional cross-functional expertise across both specialty & generic medicines.
Aug-2022: Abbott got FDA approval for Proclaim Plus, a spinal cord stimulation system featuring FlexBurst360 therapy. FlexBurst360 therapy would offer pain coverage across up to six areas of the trunk and/or limbs & allow programming that could be adjusted as a person's therapeutic demands evolve. Through Proclaim Plus, the company aimed to address its commitment to advancing the field of neurostimulation and helping people address the challenges they face while managing their chronic pain.
Apr-2022: Boehringer Ingelheim introduced RenuTend, a new stem cell therapy. This therapy enhances the healing of tendon & suspensory ligament injuries in horses. The therapy further demonstrates the company's commitment to bringing innovation with the aim to enhance the lives of horses and the people who love them.
Oct-2022: Pfizer acquired Biohaven Pharmaceuticals, a commercial-stage biopharmaceutical company. This acquisition focused on growing Pfizer's potential to bring the latest treatment options to patients with migraine.
Oct-2022: Pfizer completed the acquisition of Global Blood Therapeutics, a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments. With this acquisition, Pfizer focused on accelerating innovation & expeditiously bringing multiple potential best-in-class treatments to people living with sickle cell disease.
Jun-2022: Boehringer Ingelheim took over Trutino Biosciences, a pre-clinical stage biotech company. This acquisition would advance the company's effort to mobilize a patient's immune system and fight cancer through cancer cell-directed and immune cell-targeting compounds. Further, under this acquisition, Boehringer Ingelheim reserves the right to buy all shares of Trutino Biosciences once specified program milestones have been achieved within a specified time period. Trutino would continue to operate as an independent company until that time.
Apr-2022: GSK completed the acquisition of Sierra Oncology, a California-based, late-stage Biopharmaceutical Company. Through this acquisition, GSK would get the opportunity to bring meaningful latest benefits to patients and further strengthen its portfolio of specialty medicines.
Mar-2022: Pfizer took over Arena Pharmaceuticals, an American biopharmaceutical company. Addition of Arena Pharmaceuticals's experience and pipeline to Pfizer's Inflammation and Immunology therapeutic area, helping them to develop breakthroughs to change the lives of people with immuno-inflammatory diseases.
Nov-2021: Pfizer took over Trillium Therapeutics, a clinical stage immuno-oncology company. This acquisition aimed at enabling Pfizer to accelerate breakthroughs that change patients' lives.
Jul-2021: AstraZeneca took over Alexion Pharmaceuticals, an American pharmaceutical company. This acquisition would mark the Company's entry into medicines for rare diseases and the beginning of the latest chapter for AstraZeneca.
Nov-2020: Merck took over OncoImmune, a privately-held, clinical-stage Biopharmaceutical Company. By this acquisition, Merck would be able to access CD24Fc and take advantage beyond the standard of care therapy for COVID-19 patients requiring oxygen support and hence would represent an important addition to the Merck pipeline of investigational medicines & vaccines developed to address the COVID-19pandemic.